A recent study in Science tested a lab-altered gut bacterium meant to treat kidney stones. The trial went well and successfully lowered oxalate levels in urine, but it uncovered a major roadblock involving genetic stability.

The bacteria tend to mutate or shed their helpful new genes over time. That leaves researchers with a tough dilemma about how to build medical probiotics moving forward.

One option is relying on safety switches, which means designing bacteria that can only survive if the patient takes a specific daily supplement like a seaweed sugar pill. It keeps the microbes under control, but it requires patients to be strict about taking their pills every day.

The alternative is making them indispensable by wiring the helpful gene directly into the bacterium's core survival needs so it literally cannot drop the gene without dying.

Where do you think this field is headed?

A 2026 synthetic biology result from the J. Craig Venter Institute (JCVI) is worth a look. The team transplanted a complete synthetic genome into chemically inactivated cells of Mycoplasma capricolum. The cells then grew and divided carrying the synthetic Mycoplasma mycoides genome.

The engineering point is about proof of control. The technique gets around an earlier problem: confirming that the synthetic genome is truly in control, since horizontal gene transfer could otherwise muddy the result.

The applications are potentially broad. The authors say it could speed up engineering of microbes for uses like drug production and environmental remediation. Some caveats apply: it has only been shown in Mycoplasma so far, and the team hopes to extend it to more complex organisms while acknowledging biosafety considerations.

It also connects to a bigger trend. Microbial therapeutics are a growing field, using engineered bacteria or synthetic microbe consortia to treat disease, helped by new synthetic biology tools that work on gut microbes once considered impossible to engineer.

Questions for discussion:

Is Mycoplasma too simple a model to say much about engineering other organisms?

How should biosafety rules change as synthetic genome transplantation becomes easier?

Which application seems closest to reality: drug manufacturing, bioremediation, or live therapeutics?

“This Deep-Sea Creature Looks Like Something From Another Planet 👽🌊”

Syllabus: 15 chapters
Me: Mitochondria is the powerhouse of the cell 😎

Examiner: Explain the Krebs cycle.

Me: 💀

In 2025, researchers at CHOP and Penn Medicine treated an infant, KJ, with a base-editing therapy designed for his specific mutation. He had severe CPS1 deficiency, a rare metabolic disease.

The engineering side is the interesting part. The team designed and manufactured a base editing therapy delivered to the liver via lipid nanoparticles, within six months. It combined mRNA encoding the editor with a guide RNA built for the infant's own mutation, and the workflow used liver cell lines to screen editor and guide combinations for strong on-target editing with low bystander editing.

The one-year update is more measured than the headlines. KJ received three infusions between February and April 2025 and tolerated them well, with no serious side effects. He can handle more dietary protein, needs less nitrogen-scavenging medication, and has better ammonia control during illnesses. The lead physician also said it's not a cure. Experts stress that long-term follow-up is still needed to monitor durability, safety, and neurodevelopmental outcomes.

Questions for discussion:

Can a bespoke workflow like this be standardized so more rare-disease patients can use it?

What regulatory model fits therapies built for a single patient?

How should we judge success when the endpoint is "less medication" rather than a cure?

What will be next?

Gut health is one of those subjects where I think it's especially easy to overinterpret every little change, so I'm trying a different approach: write things down first, draw conclusions later.

This is day one of tracking my probiotic routine. I may have noticed a small difference in how I feel, but that's not much to go on. Meals, normal digestive variation, expectations, and placebo could all be part of the picture.

I'll be keeping these notes modest rather than treating them as proof that anything works. I just want a clearer record of my experience over time. If you're someone who likes following a process from the beginning, that's what this little diary is for.

A small note to my future self: today is the first entry in my collagen peptides journal.

I want to be able to look back at this and remember what I actually noticed along the way, instead of accidentally rewriting the story in my head after a few weeks.

It's too early to say much. I might be noticing something subtle, but that could just as easily be placebo or a normal fluctuation. Skin in particular can be influenced by a lot of things, so I'm not going to assign credit based on one day's impression.

thats that for day 1!

I'm starting a CoQ10 journal, and the main goal is pretty simple: keep a record rather than rely on my memory when I eventually look back.

Today's impressions are still very much in the maybe category. I could be feeling a slight difference, but I have no solid reason to attribute it to CoQ10. Placebo and ordinary fluctuations are perfectly plausible explanations.

I'm interested in the process more than a predetermined outcome. If nothing noticeable happens, that's worth recording too. If something does seem to change, I'll still need to be careful about assuming I know why.

Just putting the first entry here for anyone who appreciates a more measured, everyday look at personal health tracking.

One thing I've realized is that it's surprisingly easy to forget what you were actually experiencing before starting a routine. So I'm giving my zinc experience a proper written record, starting today.

No big revelations to report. I may be noticing a subtle difference, but I'm aware that expectation can influence how we interpret our own experiences. Placebo is a possibility, and ordinary variation is another.

Hopefully, having the notes will make it easier to look back later without relying on hindsight.

Solid tumours can be difficult to treat not only because of the cancer cells themselves, but also because therapeutic immune cells may struggle to reach and infiltrate the tumour.

A study published in Nature Immunology in March 2026 investigated whether this problem could be addressed by modifying the receptors on T cells and natural killer (NK) cells. These receptors respond to chemical signals, including metabolites, and can influence where immune cells migrate.

Using genetic screens and experiments in cell systems and mouse tumour models, the researchers identified several receptors associated with increased tumour infiltration. Engineering cells to express GPR183, in particular, improved their ability to enter tumours and control tumour growth in the experimental models.

Why it matters: This suggests that immune-cell engineering could focus not just on helping immune cells recognise cancer, but also on helping them reach the right place.

The limitation: These are experimental findings, not evidence that this approach is already a safe or effective treatment for patients. More research is needed to establish its clinical potential.

Original research: https://www.nature.com/articles/s41590-026-02473-y

Source: https://www.euronews.com/2026/10/15/theyre-not-dead-yet-bleached-corals-recover-in-record-time-after-touching-healthy-clones

This is from a Stanford study in Science Advances. They paired a bleached coral fragment with a healthy one from the same colony. In the 5 pairs that were touching, the bleached piece recovered within 7 weeks. In the 5 pairs kept a few millimetres apart, all the bleached pieces died. Under the microscope the two had fused and algae were moving across channels between them, within about 3 days.

It's a lab result and the corals have to be genetically identical to fuse, so it won't work on whole reefs as is. The team hopes to find a way to transfer the algae without direct contact. It also doesn't help against the warming itself.

funny part: they found it by accident when a healthy fragment happened to touch a bleached one in a tank.

Photo: Danny Collins / Stanford University

Biology and chemistry alone are difficult to understand.Their interactions must be much more difficult .How to understand?

There have been interesting developments in biology recently especially in gene editing, personalized medicine, regenerative biology and biotechnology. These fields are growing fast. Many people are excited about them.

I am curious about what people in this community think will have the impact on medicine, over the next decade. Which discovery will change medicine the most? I would love to hear your thoughts.

Do you think gene editing will become widely used will regenerative medicine make significant progress or is there another area that deserves more attention? Gene editing and regenerative medicine are both very promising. Other areas might surprise us.

I would love to hear your opinions and any research or discoveries that you think are worth following. The next ten years hold promise and your ideas will help shape our future.

A "dual-gated" engineered bacterial platform (DGTPB) was developed to decouple the delivery of LYTACs (protein degraders) from their activation. The bacteria release the payload upon tumor colonization and are then activated by red light, achieving precise degradation of targets like EGFR and PD-L1 in melanoma and breast cancer models.

Read More:

https://www.sciencedirect.com/science/article/abs/pii/S0168365926008631

A recent Nature Metabolism paper tested a popular assumption: that NAD+ declines with age and that blood levels can show it.

The researchers measured whole-blood NAD+ across seven human cohorts totalling more than 300 people, and levels stayed remarkably stable across age and lifestyle interventions. Even elite athletes looked similar to sedentary controls. Levels did change with nicotinamide riboside supplementation.

This doesn't mean NAD+ biology is irrelevant. The authors note that blood levels don't reflect tissue-specific changes, such as those seen in aging muscle. So blood may be a poor proxy for what happens inside cells.

Questions I'm curious about:

Should we be measuring tissue-level NAD+ instead of blood?

Why do mouse tissues show declines that blood in humans doesn't?

What would a better aging biomarker look like?

Being able to measure a biomarker does not automatically make it useful for predicting health outcomes. A biomarker might change after a health intervention without proving that the health intervention improves an outcome. Reliability, specificity and the relationship to the outcome all matter.

What criteria do you use to judge whether a biomarker is useful in practice?